Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
Endoscopic and histologic improvements with PRA023 in ARTEMIS-UC, a Phase 2 placebo-controlled study on moderately to severely active ulcerative colitis
book_2
Source:
UEG Week 2023 - Oral session
calendar_today
Published on Medfyle:
November 2023
import_contacts
5
min
In this medfyle
PRA02 (MK-7240) is under clinical development and is currently in Phase II for UC. Primary endpoint clinical remission rates have been previously reported. Here, the proportion of patients achieving endoscopic remission, endoscopic improvement, histologic improvement, and mucosal healing – endpoints associated with an improved prognosis – are reported.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
